Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Author:

Smith David A.,Conkling Paul,Richards Donald A.,Nemunaitis John J.,Boyd Thomas E.,Mita Alain C.,de La Bourdonnaye Guillaume,Wages David,Bexon Alice S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Reference37 articles.

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236

2. National Comprehensive Cancer Network (NCCN) (2012) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small cell lung cancer version 3. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed 4 Sep 2013

3. Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R et al (2011) Treatment of advanced non small cell lung cancer. J Thorac Dis 3:122–133

4. Ho C, Davies AM, Lara PN Jr, Gandara DR (2006) Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer 7(Suppl 4):S118–S125

5. Taxotere [product monograph] (2013) Revised Aug 2013. Bridgewater, NJ: sanofi-aventis U.S. LLC. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf . Accessed 16 Sep 2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3